Hepatitis Monthly

Published by: Kowsar

Plasma Level of miR-5193 as a Novel Biomarker for Diagnosis of HBV-Related Hepatocellular Carcinoma

Niloofar Moradi 1 , Mahdi Paryan 2 , * , Behzad Khansarinejad 3 , Hossein Sarmadian 4 and Mahdieh Mondanizadeh 1 , 5 , **
Authors Information
1 Department of Biotechnology and Molecular Medicine, Arak University of Medical Sciences, Arak, Iran
2 Department of Research and Development, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran
3 Department of Microbiology and Immunology, Arak University of Medical Sciences, Arak, Iran
4 Infectious Diseases Research Center, Arak University of Medical Sciences, Arak, Iran
5 Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: February 28, 2019, 19 (2); e84455
  • Published Online: February 24, 2019
  • Article Type: Research Article
  • Received: September 21, 2018
  • Revised: January 19, 2019
  • Accepted: February 14, 2019
  • DOI: 10.5812/hepatmon.84455

To Cite: Moradi N , Paryan M, Khansarinejad B , Sarmadian H, Mondanizadeh M. Plasma Level of miR-5193 as a Novel Biomarker for Diagnosis of HBV-Related Hepatocellular Carcinoma, Hepat Mon. 2019 ; 19(2):e84455. doi: 10.5812/hepatmon.84455.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: Special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014;7(4):148-55. doi: 10.1177/1756283X14524614. [PubMed: 25057295]. [PubMed Central: PMC4107707].
  • 2. World Health Organization. Hepatitis B. 2018. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
  • 3. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24(1):1-17. doi: 10.1016/j.soc.2014.09.001. [PubMed: 25444466].
  • 4. Akamatsu S, Hayes CN, Tsuge M, Miki D, Akiyama R, Abe H, et al. Differences in serum microRNA profiles in hepatitis B and C virus infection. J Infect. 2015;70(3):273-87. doi: 10.1016/j.jinf.2014.10.017. [PubMed: 25452043].
  • 5. Zhang Y, Wei C, Guo CC, Bi RX, Xie J, Guan DH, et al. Prognostic value of microRNAs in hepatocellular carcinoma: A meta-analysis. Oncotarget. 2017;8(63):107237-57. doi: 10.18632/oncotarget.20883. [PubMed: 29291025]. [PubMed Central: PMC5739810].
  • 6. Wang Y, Gao Y, Shi W, Zhai D, Rao Q, Jia X, et al. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark. 2015;15(2):171-80. doi: 10.3233/CBM-140451. [PubMed: 25519019].
  • 7. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273 e1. doi: 10.1053/j.gastro.2011.12.061. [PubMed: 22537432]. [PubMed Central: PMC3338949].
  • 8. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84-S101. doi: 10.1016/j.jhep.2016.02.021. [PubMed: 27084040].
  • 9. Tang Q, Wang Q, Zhang Q, Lin SY, Zhu Y, Yang X, et al. Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues. BMC Cancer. 2017;17(1):862. doi: 10.1186/s12885-017-3860-x. [PubMed: 29254483]. [PubMed Central: PMC5735680].
  • 10. Sun Q, Wang R, Wang Y, Luo J, Wang P, Cheng B. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma. Oncol Rep. 2014;31(2):933-9. doi: 10.3892/or.2013.2917. [PubMed: 24336972].
  • 11. Wang F, Zhou H, Yang Y, Xia X, Sun Q, Luo J, et al. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep. 2012;27(4):1170-6. doi: 10.3892/or.2012.1620. [PubMed: 22218807]. [PubMed Central: PMC3583435].
  • 12. Wang F, Xia X, Wang J, Sun Q, Luo J, Cheng B. Notch1 signaling contributes to the oncogenic effect of HBx on human hepatic cells. Biotechnol Lett. 2013;35(1):29-37. doi: 10.1007/s10529-012-1048-7. [PubMed: 22986536].
  • 13. Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 2010;52(1):142-54. doi: 10.1002/hep.23613. [PubMed: 20578140].
  • 14. Sun Q, Wang R, Luo J, Wang P, Xiong S, Liu M, et al. Notch1 promotes hepatitis B virus X protein-induced hepatocarcinogenesis via Wnt/beta-catenin pathway. Int J Oncol. 2014;45(4):1638-48. doi: 10.3892/ijo.2014.2537. [PubMed: 25017705].
  • 15. Gao J, Xiong Y, Wang Y, Wang Y, Zheng G, Xu H. Hepatitis B virus X protein activates Notch signaling by its effects on Notch1 and Notch4 in human hepatocellular carcinoma. Int J Oncol. 2016;48(1):329-37. doi: 10.3892/ijo.2015.3221. [PubMed: 26530164].
  • 16. Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442-9. doi: 10.1016/j.ejca.2013.06.002. [PubMed: 23810247].
  • 17. Lou J, Zhang L, Lv S, Zhang C, Jiang S. Biomarkers for hepatocellular carcinoma. Biomark Cancer. 2017;9:1-9. doi: 10.1177/1179299X16684640. [PubMed: 28469485]. [PubMed Central: PMC5345949].
  • 18. Mao B, Wang G. MicroRNAs involved with hepatocellular carcinoma (review). Oncol Rep. 2015;34(6):2811-20. doi: 10.3892/or.2015.4275. [PubMed: 26398882].
  • 19. Giordano S, Columbano A. MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57(2):840-7. doi: 10.1002/hep.26095. [PubMed: 23081718].
  • 20. Abedi N, Mohammadi-Yeganeh S, Koochaki A, Karami F, Paryan M. miR-141 as potential suppressor of beta-catenin in breast cancer. Tumour Biol. 2015;36(12):9895-901. doi: 10.1007/s13277-015-3738-y. [PubMed: 26164002].
  • 21. Endzelins E, Melne V, Kalnina Z, Lietuvietis V, Riekstina U, Llorente A, et al. Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: A systematic review. Mol Cancer. 2016;15(1):41. doi: 10.1186/s12943-016-0523-5. [PubMed: 27189160]. [PubMed Central: PMC4870749].
  • 22. Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, et al. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9(9). e107986. doi: 10.1371/journal.pone.0107986. [PubMed: 25238238]. [PubMed Central: PMC4169601].
  • 23. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781-8. doi: 10.1200/JCO.2011.38.2697. [PubMed: 22105822].
  • 24. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20). e179. doi: 10.1093/nar/gni178. [PubMed: 16314309]. [PubMed Central: PMC1292995].
  • 25. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9). e36. doi: 10.1093/nar/30.9.e36. [PubMed: 11972351]. [PubMed Central: PMC113859].
  • 26. Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016;231(1):25-30. doi: 10.1002/jcp.25056. [PubMed: 26031493].
  • 27. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(4):355-60. doi: 10.1097/MCG.0b013e3181f18ac2. [PubMed: 21278583].
  • 28. Pan JH, Zhou H, Zhao XX, Ding H, Li W, Qin L, et al. Role of exosomes and exosomal microRNAs in hepatocellular carcinoma: Potential in diagnosis and antitumour treatments (review). Int J Mol Med. 2018;41(4):1809-16. doi: 10.3892/ijmm.2018.3383. [PubMed: 29328436]. [PubMed Central: PMC5810235].
  • 29. Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z, et al. MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin. Biochem Biophys Res Commun. 2012;428(4):525-31. doi: 10.1016/j.bbrc.2012.10.039. [PubMed: 23068095].
  • 30. Li Y, Li Y, Chen Y, Xie Q, Dong N, Gao Y, et al. MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell Int. 2017;17:102. doi: 10.1186/s12935-017-0471-1. [PubMed: 29151817]. [PubMed Central: PMC5678695].
  • 31. Yang Y, Chang S, Zhao Z, Hou NI, He K, Wang X, et al. MicroRNA-214 suppresses the proliferation of human hepatocellular carcinoma cells by targeting E2F3. Oncol Lett. 2015;10(6):3779-84. doi: 10.3892/ol.2015.3745. [PubMed: 26788207]. [PubMed Central: PMC4665883].
  • 32. McDonald AC, Vira M, Shen J, Sanda M, Raman JD, Liao J, et al. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. Prostate. 2018;78(6):411-8. doi: 10.1002/pros.23485. [PubMed: 29383739].
  • 33. Freres P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, et al. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. 2018;18(1):102. doi: 10.1186/s12885-018-4015-4. [PubMed: 29378531]. [PubMed Central: PMC5789542].
  • 34. Xiang ZL, Zhao XM, Zhang L, Yang P, Fan J, Tang ZY, et al. MicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinoma. Oncotarget. 2016;7(52):87246-56. doi: 10.18632/oncotarget.13531. [PubMed: 27893432]. [PubMed Central: PMC5349985].
  • 35. Long LM, Zhan JK, Wang HQ, Li S, Chen YY, Liu YS. The clinical significance of miR-34a in pancreatic ductal carcinoma and associated molecular and cellular mechanisms. Pathobiology. 2017;84(1):38-48. doi: 10.1159/000447302. [PubMed: 27458977].
  • 36. Khlaiphuengsin A, T. Thienprasert NP , Tangkijvanich P, Posuwan N, Makkoch J, Poovorawan Y, et al. Human miR-5193 triggers gene silencing in multiple genotypes of hepatitis B virus. Microrna. 2015;4(2):123-30. [PubMed: 26456535].
  • 37. Sayad B, Naderi Y, Alavian SM, Najafi F, Janbakhsh A, Mansouri F, et al. Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections. Gastroenterol Hepatol Bed Bench. 2018;11(2):145-52. [PubMed: 29910856]. [PubMed Central: PMC5990919].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments